Bloomberg Audio Studios, podcasts, radio news talk us through the main growth drivers that you see when you take a look over the course of this year.
Yeah, first, Katie, thanks for having us on this morning. You know, in terms of the growth drivers, we really think there's two or three major things going on. One, unfortunately, is still all of the chronic care disease management that's occurring in the country. You know, type two diabetes at an all time high, autoimmune disorders, cancer rates, younger and younger patients being diagnosed with cancer, colon cancer in particular.
So all of this is leading to a lot of testing as you can imagine, and helping people diagnose, helping people figure out what the right therapy they should select,
and then actually monitoring the disease. Now at the other end of the spectrum, and this is really a more recent phenomenon, is all the new testing from a consumer health standpoint, So you know, prevention is all about doing something before the symptoms set in, and between our own consumer health offering and then partnerships that we've developed in the industry, we are really powering the wellness industry today.
So our relationships with Function Health, our relationships with WOOP, with Aura, we're trying to make lab testing ubiquitous to consumers, especially those that really have a focus on prevention and wellness. But really it's those two things, Katie, that are really driving the growth.
Well, I'm glad you brought up consumer health and some of the partnerships you have Loop and AURA being some of them. You also have partnerships with HYMNS and Function Health. I see as well. How do you see that part of the business evolving. How meaningful of a growth driver can that be?
Yeah, So to put all of that in context, between our own direct business, our own consumer direct business, plus our partnerships with all those that you mentioned, it's about a two hundred and fifty million dollars segment and you know, we did eleven billion dollars last year, so it's meaningful. What's more meaningful is that segment grew it over thirty percent last year, and we expect it to continue to grow, you know, you know, north of twenty percent this year.
And again, what we're seeing is just consumers taking more interest in their health. With this notion of let's prevent disease, let's try to get in front of that. You know, if we look at our business today, about two thirds of it is diagnosis of disease, you know, treatment of disease, treatment monitoring, and really only a third of our business is prevention and wellness, general health and wellness testing. Honestly, I hope over the next day decade we can flip that.
I really hope that we can be two thirds prevention and wellness and then a third of chroduct care management.
When you zoom out a bit, what are you seeing in terms of trends when it comes to what types of tests are being asked for and ordered.
Yeah, Alzheimer's Katie is a very very important set of tests that we now offer. You know, before blood based biomarkers came to fruition with respect to Alzheimer's really the gold standard where cognitive tests that physicians perform and then they would move that patient directly into imaging, whether that's
a pet CT image or an MRI image. And today what we're seeing is there's blood based biomarkers for amyloid pop plaque, for what we call these TAO bundles, and you're actually going to detect Alzheimer's at a much earlier stage than what you would see in imaging and some of the new therapies that have been brought to market by Eastside and by Lilly. These therapies generally work really really well at the earliest stages of disease on set.
So these biomarkers are playing a very very important role today. We position these blood based tests with primary care physicians as well as neurologists. You know today, if you have symptoms of Alzheimer's it can take upwards of six to eight months to get in to see a memory care specialist, and patients just don't want to wait that long because again, there's therapies available if you are diagnosed.
Because you think about what's going on at some of your peer diagnostics companies. Oncology testing has been driving just rapid growth. So how does Quest position itself in that space. I know that you recently bought Haystack Oncology, for example, but is that an area where you would consider additional deals?
Yeah, first, Katie, it's a very very important part of our business today. Most people don't know, but Quest Diagnostics has a very large anatomical pathology business. Anatomical pathology is when specimens are cut outside cut from the human body. They're tissue samples, and so we have a very We have the largest anatomical pathology business in the country where we make diagnoses of cancer every single day. Now, once you have that tumor specimen, there's several follow on tests
that are very important. The first being what type of therapy should be used to treat that cancer after treatment or potentially right after surgery. The next question is did the surgeon get it all or did the chemotherapy eradicate that disease? And we have a task you mentioned, the Haystack minimally residual disease testing that looks for very very small remnants of the cancer that may remain either post surgery or post chemotherapy. So it's a growing portion of
our portfolio of testing today. Now, in addition, we offer a lot of routine cancer tests PSA screening all sorts of different types of cancer markers at the screening phase. So all told, cancer of our eleven billion dollar portfolio today, cancer in its entirety is about a billion dollars of our portfolio.